title: LHRH-induced gonadotropin release before and after short-term therapy with cabergoline in hyperprolactinaemic patients.
abstract: Cabergoline is a new ergot derivative with long-lasting PRL lowering effect. Basal and LHRH stimulated (50 micrograms i.v.) gonadotropin secretion was evaluated before and during cabergoline treatment (0.5-2 mg/week) in 28 women with pathological hyperprolactinaemia. After 4 weeks, PRL and E2 were significantly (p less than 0.01) reduced and increased, respectively. Basal LH and FSH levels did not change. Both LH (p less than 0.05) and FSH (p less than 0.02) responsiveness to LHRH was decreased from the former to the latter test. The study underlines drug-induced variations in gonadotropin responsiveness to LHRH which are probably due to variations in the steroid milieu.
authors.affiliation: ISMI, Cattedra di Endocrinologia, Università degli Studi di Genova.
authors.forename: R
authors.initials: R
authors.lastname: Durante
authors.forename: M
authors.initials: M
authors.lastname: Giusti
authors.forename: A
authors.initials: A
authors.lastname: Carraro
authors.forename: E
authors.initials: E
authors.lastname: Porcella
mesh_terms: D000293:Adolescent; D000328:Adult; D000858:Anovulation / Q000209:etiology; D000077465:Cabergoline; D004652:Empty Sella Syndrome / Q000150:complications; D004873:Ergolines / Q000494:pharmacology / Q000627:therapeutic use*; D004958:Estradiol / Q000378:metabolism; D005260:Female; D007987:Gonadotropin-Releasing Hormone; D006065:Gonadotropins, Pituitary / Q000378:metabolism*; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000150:complications; D011388:Prolactin / Q000378:metabolism; D015175:Prolactinoma / Q000150:complications; D012636:Secretory Rate / Q000187:drug effects
chemical_list: D004873:Ergolines; D006065:Gonadotropins, Pituitary; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D011388:Prolactin; D000077465:Cabergoline